Trial Profile
Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs GLS 5700 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- Sponsors GeneOne Life Science
- 16 Sep 2021 Results published in the New England Journal of Medicine
- 31 Jul 2018 Status changed from active, no longer recruiting to completed.
- 08 Oct 2017 Results presented at the IDWeek 2017